AUSTRALIAN PHARMACEUTICAL INDUSTRIES LIMITED (API)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

API - AUSTRALIAN PHARMACEUTICAL INDUSTRIES LIMITED

FNArena Sector : Health & Nutrition
Year End: August
GICS Industry Group : Health Care Equipment & Services
Index: ASX300 | ALL-ORDS

Australian Pharmaceutical Industries is an Australian health and beauty product manufacturer and retailer. Its brand stores include Priceline, Soul Pattinson Chemist and Clear Skincare. Founded in 1910 as a chemist's co-operative, it listed in 1997.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$1.47

23 Sep
2021

-0.020

OPEN

$1.48

-1.34%

HIGH

$1.50

1,136,808

LOW

$1.47

TARGET
$1.443 -1.8% downside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
EBO . MCP . BKL . EXL . SIG . CLV .
FNARENA'S MARKET CONSENSUS FORECASTS
API: 1
Title FY19
Actual
FY20
Actual
FY21
Forecast
FY22
Forecast
EPS (cps) xxx - 1.7 7.3 xxx
DPS (cps) xxx 2.0 4.1 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx - 74.2% 100.0% xxx
PE Ratio xxx N/A 20.1 xxx
Dividend Yield xxx N/A 2.8% xxx
Div Pay Ratio(%) xxx N/A 55.6% xxx

Dividend yield today if purchased 3 years ago: 1.05%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

1.36

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 06/05 - 1.5c (100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2021 FactSet UK Limited. All rights reserved
Title 201520162017201820192020
EPS Basic xxxxxxxxxxxxxxx-1.7
DPS All xxxxxxxxxxxxxxx2.0
Sales/Revenue xxxxxxxxxxxxxxx4,019.5 M
Book Value Per Share xxxxxxxxxxxxxxx92.1
Net Operating Cash Flow xxxxxxxxxxxxxxx216.9 M
Net Profit Margin xxxxxxxxxxxxxxx-0.21 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201520162017201820192020
Return on Assets xxxxxxxxxxxxxxx-0.52 %
Return on Equity xxxxxxxxxxxxxxx-1.73 %
Return on Total Capital xxxxxxxxxxxxxxx7.22 %
Capex xxxxxxxxxxxxxxx40.0 M
Capex % of Sales xxxxxxxxxxxxxxx0.99 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx157.2 M

Return on Assets

Return on Equity

Return on Total Capital

Capex

Capex % of Sales

Free Cash Flow ex dividends

This is work in progress. Bear with us. It'll be amazing.

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

3
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Credit Suisse

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

xx/xx/xxxx

3

xxxxx-xxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

30/07/2021

3

Neutral

$1.38

-6.12%

Australian Pharmaceutical Industries has rejected Wesfarmers ((WES)) proposal to acquire the company at $1.38/share stating that the 18.7% premium to 3-month volume weight average price (VWAP) of $1.163 is “significantly below the Australian market average for transactions of this nature.”

Citi continues to expect a transaction is more likely than not, and notes applying the long-term average takeover premium of 30% to the
3-month VWAP implies a price of $1.51/share or an additional $65m over the original proposal.

Neutral rating and target price of $1.38 are both retained.

FORECAST
Citi forecasts a full year FY21 dividend of 4.30 cents and EPS of 8.20 cents.
Citi forecasts a full year FY22 dividend of 7.30 cents and EPS of 9.00 cents.

Macquarie

xx/xx/xxxx

-1

xx xxxxxx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

API STOCK CHART